Abstract:One of the most significant reasons hindering the clinical translation of nanomedicines is the rapid clearance of intravenously injected nanoparticles by the mononuclear phagocyte system, particularly by Kupffer cells in the liver, leading to an inefficient delivery of nanomedicines for tumor treatment. The threshold theory suggests that the liver's capacity to clear nanoparticles is limited, and a single high dose of nanoparticles can reduce the hepatic clearance efficiency, allowing more nanomedicines to reach tumor tissues and enhance therapeutic efficacy. Building upon this theory, researchers have conducted numerous validation studies based on the same nanoparticle carrier systems. These studies involve the use of albumin nanoparticles to improve the therapeutic efficacy of albumin nanomedicines as well as polyethylene glycol (PEG)-modified liposomal nanoparticles to enhance the efficacy of PEGylated liposomal nanomedicines. However, there is no research indicating the feasibility of the threshold theory when blank nanoparticles and nanomedicine belong to different nanoparticle carrier systems currently. In this study, we prepared two different sizes of albumin nanoparticles by using bovine serum albumin. We used the marketed nanomedicine liposomal doxorubicin hydrochloride injection (trade name: LIBOD, manufacturer: Shanghai Fudan-zhangjiang Biopharmaceutical Co., Ltd.), as the representative nanomedicine. Through in vivo experiments, we found that using threshold doses of albumin nanoparticles still can reduce the clearance rate of LIBOD, prolong its time in vivo, increase the area under the plasma concentration-time curve (AUC), and also lead to an increased accumulation of the drug at the tumor site. Furthermore, evaluation of in vivo efficacy and safety further indicates that threshold doses of 100 nm albumin nanoparticles can enhance the antitumor effect of LIBOD without causing harm to the animals. During the study, we found that the particle size of albumin nanoparticles influenced the in vivo distribution of the nanomedicine at the same threshold dose. Compared with 200 nm albumin nanoparticles, 100 nm albumin nanoparticles more effectively reduce the clearance efficiency of LIBOD and enhance nanomedicine accumulation at the tumor site, warranting further investigation. This study utilized albumin nanoparticles to reduce hepatic clearance efficiency and enhance the delivery efficiency of nonalbumin nanocarrier liposomal nanomedicine, providing a new avenue to improve the efficacy and clinical translation of nanomedicines with different carrier systems.

The proliferation inhibition of K562 cells by albumin nanoparticles with As;O

The Proliferation Inhibition of K562 Cells by Albumin Nanoparticles with As2O3

Preparation of Arsenic Trioxide-Loaded Albuminutes Immuno-Nanospheres and Its Specific Killing Effect on Bladder Cancer Cell in Vitro

Novel Strategy to Fabricate PLA/Au Nanocomposites As an Efficient Drug Carrier for Human Leukemia Cells in Vitro

Arsenic trioxide nanoparticles inhibit acute promyelocytic leukemia cell proliferation and induce apoptosis via PTEN/AKT signalling pathway

Albumin Nanoparticle Encapsulation of Potent Cytotoxic Therapeutics Shows Sustained Drug Release and Alleviates Cancer Drug Toxicity.

Uptake of albumin nanoparticles by NB4 cells and the anti-tumor effect of dihydrotanshinone Ⅰ loaded albumin nanoparticles on the cells

Albumin As a "trojan Horse" for Polymeric Nanoconjugate Transendothelial Transport Across Tumor Vasculatures for Improved Cancer Targeting

Effects of As2O3 Nanoparticles on Cell Growth and Apoptosis of NB4 Cells.

Enhanced Cytotoxicity Suppression of Arsenic Trioxide to Leukemia Cancer Cells by Using Magnetic Nanoparticles

Combination of small interfering RNA-directed B cell lymphoma/leukemia-2 oncogene silencing and arsenic using a nanomedicine strategy for the enhanced cytotoxicity of acute myelogenous leukemia in vitro

Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory

Erythrocyte Membrane-Coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy.

Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy

Preparation and evaluation of As2O3 nanoparticles for treatment of human liver cancer cells in vitro

Albumin modified cationic nanocarriers to potentially create a new platform for drug delivery systems.

Study on inhibitory effects of RGD-conjugated gemcitabine-loaded albumin nanoparticles on the proliferation of BxPC-3 cells in vitro

Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC

Preparation and Characterization of Erythrocyte Membrane Cloaked PLGA/arsenic Trioxide Nanoparticles and Evaluation of Their in Vitro Anti-Tumor Effect

Experimental Study of As2O3 Nanoparticles in the Therapy of Acute Promyelocytic Leukemia

Preparation of Liver-targeted Nano-prodrug Based on Sodium Alginate Derivative and the Study on Antitumor Activity